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Stem Cell Types and Subpopulations Reveals
Superior Paracrine Potency and Myocardial
Repair Efficacy With Cardiosphere-Derived Cells
Tao-Sheng Li, MD, PHD,*† Ke Cheng, PHD,* Konstantinos Malliaras, MD,*
Rachel Ruckdeschel Smith, PHD,*‡ Yiqiang Zhang, PHD,* Baiming Sun, MD,*
Noriko Matsushita, MD, PHD,* Agnieszka Blusztajn, BS,‡ John Terrovitis, MD,§
Hideo Kusuoka, MD, PHD, Linda Marba´n, PHD,*‡ Eduardo Marba´n, MD, PHD*
Los Angeles, California; Nagasaki and Osaka, Japan; and Athens, Greece
Objectives The goal of this study was to conduct a direct head-to-head comparison of different stem cell types in vitro for various
assays of potency and in vivo for functional myocardial repair in the samemouse model of myocardial infarction.
Background Adult stem cells of diverse origins (e.g., bone marrow, fat, heart) and antigenic identity have been studied for
repair of the damaged heart, but the relative utility of the various cell types remains unclear.
Methods Human cardiosphere-derived cells (CDCs), bone marrow–derived mesenchymal stem cells, adipose tissue–
derived mesenchymal stem cells, and bone marrow mononuclear cells were compared.
Results CDCs revealed a distinctive phenotype with uniform expression of CD105, partial expression of c-kit and CD90,
and negligible expression of hematopoietic markers. In vitro, CDCs showed the greatest myogenic differentiation
potency, highest angiogenic potential, and relatively high production of various angiogenic and antiapoptotic-
secreted factors. In vivo, injection of CDCs into the infarcted mouse hearts resulted in superior improvement of
cardiac function, the highest cell engraftment and myogenic differentiation rates, and the least-abnormal heart
morphology 3 weeks after treatment. CDC-treated hearts also exhibited the lowest number of apoptotic cells.
The c-kit subpopulation purified from CDCs produced lower levels of paracrine factors and inferior functional
benefit when compared with unsorted CDCs. To validate the comparison of cells from various human donors,
selected results were confirmed in cells of different types derived from individual rats.
Conclusions CDCs exhibited a balanced profile of paracrine factor production and, among various comparator cell types/sub-
populations, provided the greatest functional benefit in experimental myocardial infarction. (J Am Coll Cardiol
2012;59:942–53) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.11.029It is now recognized that resident cardiac stem cells exist in
the adult mammalian heart, including mouse, rat, and
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2011, accepted November 22, 2011.human (1–7). Several groups have expanded the small
population of cardiac stem cells from adult human heart
tissue with a view to clinical applications in regenerative
therapy (7–9). We have developed a technique to expand tens of
millions of cardiosphere-derived cells (CDCs), a mixture of
cardiac stem cells and supporting cells, from percutaneous
endomyocardial biopsies (8). This technology is in Phase I
clinical study for the treatment of post-ischemic heart failure
(CADUCEUS [Cardiosphere-Derived Autologous Stem
Cells to Reverse Ventricular Dysfunction; NCT00893360]).
Nevertheless, heart-derived cells are relative newcomers to
regenerative cardiology.
Multiple extracardiac cell sources, including bone marrow
mononuclear cells (BM-MNCs), bone marrow–derived
mesenchymal stem cells (BM-MSCs), adipose tissue–
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March 6, 2012:942–53 Myocardial Repair by Different Types of Stem Cellsderived mesenchymal stem cells (AD-MSCs), endothelial
progenitor cells, and myoblasts, have been used clinically in
attempts to regenerate the damaged heart (10–18). The
implantation of these cells of extracardiac origin has been
found to produce generally positive effects, mostly through
paracrine mechanisms (19–22). Although resident cardiac
stem cells can mediate direct cardiogenesis and angiogenesis
(1–7,23,24), recent studies have found that even these cells
exert most of their benefits via indirect paracrine mechanisms
(25,26). Therefore, no convincing evidence supports the supe-
riority of heart-derived cells for myocardial repair. Even within
heart-derived cells, 2 cell products are in clinical trials, but these
have yet to be compared directly. The first, CDCs, are a
natural mixture of stromal, mesenchymal, and progenitor cells
(8); the second cell product represents the c-kit subpopulation
purified from mixed heart-derived cells (1,9).
In the current study, we performed a head-to-head compar-
ison of different stem cell types/subpopulations for functional
myocardial repair by assessing multiple in vitro parameters,
including secretion of relevant growth factors, and in vivo cell
implantation into an acute myocardial infarction model in
severe combined immunodeficiency (SCID) mice.
Methods
Cell sources. Human CDCs were expanded as previously
described from minimally invasive endomyocardial biopsies
(27). Human BM-MSCs and BM-MNCs were purchased
from Lonza (Walkersville, Maryland). Human AD-MSCs
were purchased from Invitrogen (Carlsbad, California).
These cells were freshly isolated from healthy donors. The
c-kit stem cell subpopulation was purified from CDCs
sing a CELLection Pan Mouse IgG Kit and a Dynal
PC-15 magnetic particle concentrator (Invitrogen).
For confirmatory rat studies, 4-month-old Wistar Kyoto
ats were used to expand CDCs, BM-MSCs, and AD-
SCs, as described previously (23,28,29). BM-MNCs
ere also collected from the same rats by using gradient
entrifugation (19). Freshly collected BM-MNCs and
wice-passaged CDCs, BM-MSCs, and AD-MSCs were
sed for rat experiments.
Unless otherwise noted, basic Iscove’s modified Dulbec-
o’s medium (IMDM) (Invitrogen) supplemented with 10%
etal bovine serum (Thermo Scientific HyClone) and gen-
amycin 20 mg/ml were used to culture all cell lines.
low cytometry. The identity of CDCs, BM-MSCs,
D-MSCs, and BM-MNCs was investigated using flow
ytometry, as described previously (6,8). Briefly, cells were
ncubated with fluorescein isothiocyanate 7– or phycoerythrin-
onjugated antibodies against CD29, CD31, CD34, CD45,
D90, CD105, CD117 (c-kit), and CD133 (eBioscience,
nc., San Diego, California) for 30 min. Isotype-identical
ntibodies served as negative controls. Quantitative anal-
sis was performed using a CYAN-ADP flow cytometer
ith Summit 4.3 software (Beckman Coulter, Brea,
alifornia) (6,8). Enzyme-linked immunoadsorbent
ssay. To compare the potency of
he production of growth factors,
ells were seeded in 24-well culture
lates at densities of 1  106/ml
BM-MNCs) or 1  105/ml (all
other cell types) in fetal bovine se-
rum–free IMDM media (all cell
types) for 3 days. The supernatants
were collected, and the concentra-
tions of angiopoietin-2, basic fibro-
blast growth factor (bFGF), hepato-
cyte growth factor (HGF),
insulin-like growth factor (IGF)-1,
platelet-derived growth factor, stro-
mal cell–derived factor (SDF)-1,
and vascular endothelial growth fac-
tor (VEGF) were measured with
human enzyme-linked immunoad-
sorbent assay (ELISA) kits (R&D
Systems Inc., Minneapolis, Minne-
sota), according to the manufactur-
er’s instructions. Given the limited
number of rat-specific ELISA kits,
we only measured the concentra-
tions of HGF (B-Bridge Interna-
tional, Inc., Cupertino, California),
IGF-1, and VEGF in the superna-
tant with 3 days’ culture of rat cells
(R&D Systems Inc.).
To compare the production of
growth factors from the purified
c-kit subpopulation and unsorted
CDCs, we seeded cells (5 104/ml)
on 24-well culture plates and culture
for 2 days under 20% O2. Growth
actors in conditioned media were
easured by using ELISA as de-
cribed earlier.
mmunostaining. To determine myogenic differentiation
n vitro, cells were seeded on fibronectin-coated, 4-chamber
ulture slides. After 7 days of culture, cells were fixed,
locked with goat serum for 30 min, and then incubated
ith mouse anti-human troponin T antibody (R&D Sys-
ems Inc.) for human cells or with goat anti-rat troponin T
ntibody for rat cells. After 1 h of incubation at room
emperature, culture slides were washed and then incubated
ith a phycoerythrin-conjugated secondary antibody. Cell
uclei were stained with 4’-6-diamidino-2-phenylindole.
ardiomyogenic differentiation was quantified by counting
ositively stained cells.
n vitro angiogenesis assay. Angiogenic potency was as-
ayed by tube formation using a kit (Chemicon Interna-
ional Inc., Temecula, California), according to the manu-
acturer’s instructions. Briefly, cells were seeded on
Abbreviations
and Acronyms
-SA  -sarcomeric actin
AD-MSCs  adipose
tissue–derived
mesenchymal stem cells
bFGF  basic fibroblast
growth factor
BM-MNCs  bone marrow
mononuclear cells
BM-MSCs  bone marrow–
derived mesenchymal stem
cells
CDCs  cardiosphere-
derived cells
ELISA  enzyme-linked
immunoadsorbent assay
HGF  hepatocyte growth
factor
HNA  human nuclear
antigen
IGF  insulin-like growth
factor
IMDM  Iscove’s modified
Dulbecco’s medium
LV  left ventricular
LVEF  left ventricular
ejection fraction
PCR  polymerase chain
reaction
SCID  severe combined
immunodeficiency
SDF  stromal cell–derived
factor
TUNEL  terminal deoxy-
nucleotidyl transferase dUTP
nick end labeling
VEGF  vascular
endothelial growth factorCMatrix-coated 96-well plates at a density of 2 105 cells
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Myocardial Repair by Different Types of Stem Cells March 6, 2012:942–53(BM-MNCs) or 2  104 cells (all other cell types) per well.
uman umbilical vein endothelial cells were included as
ositive controls. After 6 h, tube formation was imaged.
he total tube length was then measured by using Image-
ro Plus software version 5.1.2 (Media Cybernetics, Inc.,
arlsbad, California).
erminal deoxynucleotidyl transferase dUTP nick end
abeling assay. To quantify the resistance to oxidative
tress in vitro, cells were seeded on fibronectin-coated,
-chamber culture slides. After 24 h of culture, cells were
ultured with or without the addition of 100 M H2O2 to
the medium for another 24 h. Cells were fixed, and
apoptotic cells were detected by terminal deoxynucleotidyl
transferase dUTP nick end labeling (TUNEL) assay using
the In Situ Cell Death Detection Kit (Roche Diagnostics,
Mannheim, Germany) according to the manufacturer’s
instructions. Cell nuclei were stained with 4’-6-diamidino-
2-phenylindole; apoptotic cells were counted according to
TUNEL-positive nuclei.
Myocardial infarction model and cell implantation.
Acute myocardial infarction was created in male SCID-
beige mice (10 to 12 weeks old), as described previously
(6,8). Briefly, just after ligation of the left anterior descend-
ing artery with 9-0 prolene, hearts were injected at 4 points
in the infarct border zone with a total of 40 l of one of the
ollowing interventions: phosphate-buffered saline (control,
 8), 1  105 CDCs (n  20), 1 105 BM-MSCs (n 
0), 1  105 AD-MSCs (n  20), 1  106 BM-MNCs
high BM-MNCs, n  11), or 1  105 BM-MNCs (low
M-MNCs, n  9). We studied 2 dosages in BM-MNCs,
ncluding one with 10-fold more cells than in the compar-
tor groups, because MNCs are smaller than the other cell
ypes (19) and we did not want to bias against them in terms
f total transplanted cell mass.
To compare the c-kit stem cell subpopulation purified
from CDCs with the unsorted CDCs, we performed a
separate study by injecting 1  105 purified c-kit cells
(c-kit, n  16) and 1  105 unsorted CDCs (unsorted,
n  11) into the infarcted hearts of SCID mice, using the
methods described earlier.
Echocardiography. Mice underwent echocardiography 3 h
(baseline) and 3 weeks after surgery by using the Vevo 770
Imaging System (VisualSonics, Toronto, Ontario, Canada)
(8). After the induction of light general anesthesia, the
hearts were imaged 2-dimensionally in long-axis views at
the level of the greatest left ventricular (LV) diameter. LV
end-diastolic volume, LV end-systolic volume, and LV
ejection fraction (LVEF) were measured with VisualSonics
version 1.3.8 software from 2-dimensional long-axis views
taken through the infarcted area. Blinded reading of echo-
cardiography was conducted independently by 2 experi-
enced echocardiographers (K.M. and J.T.). The results
correlated well (R2  0.66 and 0.73 for baseline and 3
weeks’ measurement, respectively) (Online Fig. 1). A
Bland-Altman plot indicated the limit of agreement to be
from –14.07 to 13.56 (30). Thus, the averages of the 2 vreadings for LVEF in each mouse were used for statistical
analysis.
Histology. Mice were sacrificed 3 weeks after treatment.
Hearts were sectioned in 5-m sections and fixed with 4%
paraformaldehyde. The engraftment of implanted human
cells was identified by immunostaining for human nuclear
antigen (HNA; Chemicon International Inc.). To measure
cell engraftment, 10 images of the infarct and border zones
were selected randomly from each animal. To quantify the
apoptotic cells in the heart, slides were fixed and apoptotic
cells were detected by TUNEL assay as described earlier.
The differentiation of implanted human cells into car-
diomyocytes in the infarcted hearts of SCID mice was
identified by immunostaining with monoclonal antibodies
against human-specific -sarcomeric actin (-SA) (Sigma-
ldrich), as described previously (8,31). For morphometric
nalysis, animals in each group were euthanized at 3 weeks
after cardiac function assessment), and the hearts were
arvested and frozen in optimal cutting temperature com-
ound. Sections every 100 m (5-m thick) were prepared.
asson’s trichrome staining was performed per manufac-
urer’s instructions (HT15 Trichrome Stain [Masson] Kit;
igma). Images were acquired with a PathScan Enabler IV
lide scanner (Advanced Imaging Concepts, Princeton,
ew Jersey). From the Masson’s trichrome-stained images,
orphometric parameters (including infarct wall thickness
nd infarct perimeter) were measured in each section with
IH ImageJ software (8,31).
uantification of engraftment by real-time polymerase
hain reaction. Quantitative polymerase chain reaction
PCR) was performed 3 weeks after cell injection to
uantify cell engraftment. Male human cells were injected
o enable detection of the SRY gene located on the Y
hromosome as a marker of engrafted cells (31). The whole
ouse heart was harvested, weighed, and homogenized.
he TaqMan assay was used to quantify the number of
ransplanted cells with the human SRY gene as template
Applied Biosystems, Foster City, California). A standard
urve was generated with multiple dilutions of genomic
NA isolated from the injected CDCs to quantify the
bsolute gene copy numbers. All samples were spiked with
qual amounts of genomic DNA from noninjected mouse
earts as a control. For each reaction, 50 ng of genomic
NA was used. Real-time PCR was performed in triplicate
ith an Applied Biosystems 7900 HT Fast real-time PCR
achine. The number of engrafted cells per heart was
uantified from the standard curve.
tatistical analysis. Statistical analysis was performed in-
ependently (by H.K.). All results are presented as mean 
D except as noted. Data sets were first tested for normality
Kolmogorov-Smirnov test) and variance (Levene’s test). If
oth were assured, statistical significance was determined by
-way analysis of variance followed by post hoc test (SPSS
I, SPSS Inc., Chicago, Illinois). If either normality or
ariance tests failed, nonparametric tests (Kruskal-Wallis
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March 6, 2012:942–53 Myocardial Repair by Different Types of Stem Cellstest followed by Dunn’s post-test) were used. Differences
were considered statistically significant when p  0.05.
Results
Characterization of cell phenotypes. Unlike BM-MNCs,
which grow in suspension as small round cells, all other cell
types studied (CDCs, BM-MSCs, and AD-MSCs) typi-
cally grow as adherent monolayers (Fig. 1A). Flow cytom-
etry distinguished BM-MNCs from other cell types by the
predominant expression of pan-hematopoietic marker
CD45 (74.7%), compared with1% in CDCs, BM-MSCs,
and AD-MSCs (Fig. 1B). Conversely, 99% of CDCs,
BM-MSCs, and AD-MSCs expressed CD105, a trans-
forming growth factor–beta receptor subunit commonly
associated with MSCs. However, these 3 cell types can be
distinguished by CD90: 99% of BM-MSCs and 85% of
D-MSCs expressed CD90 but only 18% of CDCs did so.
D90 (well known as Thy-1) was originally discovered as a
hymocyte antigen (32). In humans, Thy-1 is also expressed
y endothelial cells, smooth muscle cells, a subset of
D34 bone marrow cells, and umbilical cord blood–,
broblast-, and fetal liver–derived hematopoietic cells.
D90 is widely used as a marker of a variety of stem cells
e.g., MSCs, hepatic stem cells, keratinocyte stem cells,
utative endometrial progenitor/stem cells, hematopoietic
tem cells) (33,34). On the basis of these findings, CDCs
eem to contain a minority of fibroblast and/or weakly
ommitted hematopoietic cells, whereas such populations
ominate in the cells of bone marrow and adipose origins.
Figure 1 Morphology and Phenotype Characterization
(A) Representative images of cardiosphere-derived cells (CDCs), bone marrow–de
cells (AD-MSCs), and bone marrow–derived mononuclear cells (BM-MNCs) after 3
growth and stromal (mesenchymal) cell-like morphology; BM-MNCs have smaller s
CD117 (c-kit), and CD133 in CDCs, BM-MSCs, AD-MSCs, and BM-MNCs. Bar  50Alternatively, the CD90 in CDCs may simply mark the
cardiac mesenchymal subpopulation.
In vitro secretion of growth factors. Increasing evidence
supports the generalization that cell therapy boosts cardiac
function largely via paracrine mechanisms (25). We thus
compared the production of 6 growth factors (angiopoietin-2,
bFGF, HGF, IGF-1, SDF-1, and VEGF) by the various
cell types. CDCs were unique in their ability to secrete large
amounts of all growth factors (Fig. 2A). In contrast, the
other cell types failed to express meaningful levels of 1 or
more growth factors: BM-MNCs produced little VEGF
and SDF-1; BM-MSCs secreted little IGF-1 and bFGF;
and AD-MSCs were not rich sources of HGF and SDF-1.
Figure 2B depicts schematically the secretion of each of the
6 cytokines in each given cell type, as wheel-and-spoke
diagrams in which the length of each spoke is propor-
tional to the growth factor concentration in conditioned
media. The symmetrical starburst pattern highlights the
relatively high and distributed paracrine factor produc-
tion of CDCs.
One limitation of our comparison is that we used 10-fold
higher concentrations of BM-MNCs in these experiments,
with the rationale that these cells are much smaller than the
other 3 cell types (24) and thus have a lower secretory
biomass. Another limitation of our comparison is the fact
that the various human cell types originated from different
subjects. To ensure that the findings did not simply reflect
donor-specific idiosyncrasies, we compared growth factor
secretion by the various cell types derived from individual
esenchymal stem cells (BM-MSCs), adipose tissue–derived mesenchymal stem
n culture under 20% O2. CDCs, BM-MSCs, and AD-MSCs demonstrated adherent
round shape. (B) Expression profile of CD29, CD31, CD34, CD45, CD90,rived m
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Myocardial Repair by Different Types of Stem Cells March 6, 2012:942–53rats. In agreement with the findings in human stem cells,
higher levels of HGF, IGF-1, and VEGF were also
observed in media conditioned by rat CDCs than by rat
BM-MSCs, AD-MSCs, and BM-MNCs, all collected
from the same animals (Online Fig. 2). The well-balanced
release of growth factors in vitro confirms the notion that
CDCs are particularly rich biological factories (25,35), a
feature that may favor enhanced myocardial repair through
paracrine mechanisms after implantation into the heart.
Cardiomyogenic differentiation. Another potential ad-
vantage of CDCs is their reported ability to differentiate
into cardiomyocytes (8,24,25,31), although this propensity
has not been compared quantitatively with other cell types.
We therefore examined the ability to undergo spontaneous
cardiomyogenic differentiation in vitro by immunostaining
for cardiac-specific troponin T. Many human CDCs ex-
pressed troponin T (Fig. 3A), in contrast to human BM-
MSCs, AD-MSCs, or BM-MNCs, few of which were
positive for troponin T. Quantitative analysis revealed that
approximately 9% of CDCs expressed troponin T, whereas
Figure 2 Comparison of In Vitro Production of Growth Factors F
(A) Concentrations of angiopoietin-2, basic fibroblast growth factor (bFGF), hepato
(SDF)-1, and vascular endothelial growth factor (VEGF) measured by using enzyme
secretion of each of the 6 cytokines in each given cell type, as wheel-and-spoke d
tration in conditioned media and is normalized to that from CDCs. The symmetrica
Abbreviations as in Figure 1.1% did so in the other cell types (Fig. 3B). Similar wfindings were observed using rat CDCs, BM-MSCs, AD-
MSCs, and BM-MNCs, all collected from the same ani-
mals (Online Fig. 3).
Tube formation. We quantified the angiogenic ability of
the various cell types using an in vitro tube-forming assay
(36). All cell types could form capillary-like networks on
Matrigel (BD Biosciences, Bedford, Massachusetts) within
6 h, with the exception of BM-MNCs (Fig. 3C). Quanti-
tative analysis revealed that the mean tube length of the
capillary-like networks was greater in CDCs than in the
other cell types (p  0.05) (Fig. 3D). Thus, CDCs, at least
y this simple in vitro assay, are superior in mediating the
ormation of capillary-like structures.
esistance to oxidative stress. Enhanced cell resilience to
xidative stress favors transplanted cell engraftment and
unctional benefit (35). We assayed sensitivity to oxidative
tress by exposing cells to H2O2, a powerful oxidant. After
4 h of exposure to 100 M of H2O2, the number of
poptotic cells tended to be lower in human CDCs than in
uman BM-MNCs (p  0.067) (Online Fig. 4), but there
Cultured Cells
owth factor (HGF), insulin-like growth factor (IGF)-1, stromal cell–derived factor
immunoadsorbent assay (n  3) are depicted. (B) Schematic depicting the
s in which the length of each spoke is proportional to the growth factor concen-
urst pattern highlights the uniquely well-balanced paracrine profile of CDCs.rom
cyte gr
-linked
iagram
l starbas no significant difference among CDCs, BM-MSCs,
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March 6, 2012:942–53 Myocardial Repair by Different Types of Stem Cellsand AD-MSCs. In rat cells, higher apoptosis was observed
in BM-MNCs compared with any of the other 3 cell types
after H2O2 exposure (p  0.05) (Online Fig. 5). Taken
together, these data highlight a relative deficiency of BM-
MNCs in terms of resistance to oxidative stress.
Cell engraftment and in vivo differentiation. Although
most of the benefit of cell therapy is now recognized to be
indirect, study after study has revealed a positive correlation
between long-term cell engraftment and functional benefit
(10,19–22,25). We therefore evaluated the engraftment and
differentiation of human cells 3 weeks after direct intramyo-
cardial injection into the infarcted hearts of SCID mice.
Consistent with previous reports (7,8,23–25,31), histology
results revealed expression of -SA in some of the surviving
progeny of human CDCs (positive for HNA) (Fig. 4A),
confirming the cardiomyogenic differentiation in vivo. In
contrast, human cells positive for -SA were observed rarely
and inconsistently in mice injected with BM-MSCs, AD-
MSCs, and BM-MNCs (data not shown). Quantitative
image analysis confirmed that the engraftment (i.e., the
numbers of HNAcells) was greater in mice implanted with
human CDCs than with comparator cells (p  0.05) (Fig.
4B). In addition, the numbers of cardiomyocytes derived
from the transplanted cells (HNA/-SA) were greater in
Figure 3 In vitro Myogenic Differentiation and Angiogenesis As
(A) Troponin T, with distinct myocyte-like appearance, was expressed spontaneous
expressed in BM-MSCs, AD-MSCs, and BM-MNCs. (B) Quantitative analysis of trop
tive), and AD-MSCs and BM-MNCs (approximately 0.1% positive). (C) CDCs, BM-M
MNCs did not form similar structures under these conditions. (D) Quantitation and
Abbreviations as in Figure 1.ice implanted with human CDCs than with any of the mther cell types (p  0.01) (Fig. 4C). Quantitative PCR
onfirmed the histological analysis: more human cells were
etected in the CDC group than in the low BM-MNC
roup (p  0.05) (Fig. 4D) 3 weeks after injection. Also,
ccording to PCR analysis, there was a trend indicating
igher engraftment in the CDC group than in the BM-
SC and AD-MSC groups.
ell apoptosis. In addition to tissue regeneration, tissue
reservation may be a salutary component of cell therapy for
cute myocardial infarction (25). To evaluate this possibil-
ty, we quantified apoptotic nuclei in infarcts of control mice
nd mice injected with each of the comparator cell types.
UNEL staining revealed apoptotic nuclei in the infarcted
earts 3 weeks after treatment (Figs. 5A and 5B). We
ounted the total number of apoptotic cells in the infarct
nd peri-infarct area. The hearts of mice implanted with
DCs exhibited fewer TUNEL-positive cells, compared
ith all other cell-treated groups (p  0.05) (Fig. 5C). We
peculate that this enhanced tissue preservation may be due
o the larger amount of pro-angiogenic and antiapoptotic
actors produced by CDCs (19,25,35).
ardiac function. The most meaningful indicator of cell
otency, in practice, is the ability to produce functional
enefit after transplantation into the injured heart. We
fraction of CDCs cultured for 7 days. This cardiac-specific marker was rarely
expression (n  3) in CDCs (9% of the cells positive), BM-MSCs (0.4% posi-
nd AD-MSCs produced capillary-like tube formations in extracellular matrix. BM-
rison of tube formation capacity by the different cell types (n  3). Bars  50 m.say
ly in a
onin T
SCs, a
compaeasured cardiac function by using echocardiography, and
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Myocardial Repair by Different Types of Stem Cells March 6, 2012:942–53all images were interpreted blindly and independently by 2
experienced echocardiographers. Figure 6 summarizes the
results. The LVEF at baseline (i.e., 2 h post-infarction) was
comparable, indicating similar ischemic injury among
groups. Among the various treatments, the implantation of
CDCs resulted in the greatest LEVF at 3 weeks, and it is
the only group that was significantly better than the controls
(p 0.05 vs. control). The other cell types, although higher
on average than controls, had no clear functional benefit
statistically. Echocardiography also revealed smaller end-
diastolic and end-systolic LV volumes in the CDC-treated
animals (Online Fig. 6).
Ventricular remodeling. Potentiating the functional ben-
efits of cell therapy is attenuation of adverse ventricular
remodeling (8). To evaluate this process, we examined the
morphological consequences of transplantation of the vari-
ous cell types on myocardial infarct size and wall thinning.
Heart morphometry at 3 weeks revealed severe LV chamber
dilation and infarct wall thinning in the control hearts (Fig. 7A,
Online Fig. 7). In contrast, all the cell-treated groups
exhibited attenuated LV remodeling. Compared with con-
trols, the implantation of any type of human cells decreased
fractional infarct perimeter and, conversely, increased the
Figure 4 Cell Engraftment and In Vivo Myogenic Differentiation
(A) Immunostaining shows some human CDCs (green; human nuclear antigen [HN
after implantation into infarcted mice hearts. (B) Quantitation of engraftment (HNA
cells (HNA/-SAcells). Bar  20 um. (D) Quantitation of engraftment by usi
4’,6-diamidino-2-phenylindole; other abbreviations as in Figure 1.minimal infarct wall thickness 3 weeks after treatment (p  p0.05 vs. control group). The protective effect was greatest in
the CDC-treated hearts, which had thicker infarcted walls
(p  0.01) (Fig. 7B) but a smaller fractional infarct
erimeter (p  0.05) (Fig. 7C) than any of the other
ell-treated groups.
nsortedCDCs versus the c-kit–purified cell subpopulation.
Having established that CDCs are the most effective cell
type among those studied, we moved on to consider how
CDCs compare with purified c-kit cells. This comparison
is germane because c-kit has been argued to identify cardiac
stem/progenitor cells (1,7–9), and a purified c-kit cardiac-
erived cell product is currently being tested clinically. Therefore,
n a separate study, we compared unsorted CDCs with equal
umbers of c-kit stem cells purified from CDCs by using
agnetic cell sorting. Purified c-kit cells were inferior to
nsorted CDCs in terms of functional benefit after trans-
lantation into the infarcted heart, although they did outper-
orm vehicle-injected controls (Fig. 8A). The sorting procedure
tself did not compromise cell functional efficacy, as CDCs
orted for CD105 (expressed by 99% of CDCs) exhibited
n LVEF comparable to that of unsorted CDCs (data not
hown). To investigate one potential mechanism for the
unctional superiority of CDCs, we measured a variety of
pressing -sarcomeric actin (-SA), indicating myogenic differentiation, 3 weeks
ls). (C) Quantitation of cardiomyocytes differentiated from transplanted human
ntitative polymerase chain reaction (PCR) (n  3 mice per group). DAPI A]) ex
 cel
ng quaaracrine factors in conditioned media from sorted and
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amounts of paracrine factors in vitro compared with purified
c-kit cells (Fig. 8B), providing one potential rationale for
heir enhanced benefit.
iscussion
y head-to-head direct comparison, we demonstrated a
unctional superiority of heart-derived cells compared with
types of adult stem cells of extracardiac origin: BM-
NCs, and MSCs from bone marrow or adipose tissue.
urthermore, the superiority of CDCs for myocardial repair
as consistent with their well-balanced secretion of para-
Figure 5 Cell Apoptosis
Representative images of terminal deoxynucleotidyl transferase dUTP nick end lab
with (A) CDCs and (B) phosphate-buffered saline. (C) Quantitative assessment of
control, is shown (n  3 mice per group). Bar  500 um. Abbreviations as in Figu
Figure 6 Cardiac Function
Left ventricular ejection fraction (LVEF) at baseline (4 h post–myocardial infarc-
tion) did not differ among groups, indicating a similar infarct size in animals of
all groups. After 3 weeks, LVEF was higher in mice implanted with CDCs, com-
pared with controls injected with saline only. Differences between any other 2
groups were not significant. Data are presented as mean  SEM. Abbrevia-
tions as in Figure 1.rine factors as well as their higher cardiomyogenic differ-
ntiation capacity and engraftment, although further in vivo
ntervention experiments (e.g., with blocking antibodies)
ill be required to identify the precise mechanisms of
unctional superiority.
We selected 4 cell types for comparison that have been
sed clinically and are considered among the most promis-
ng at present for myocardial repair/regeneration. Previous
tudies (19–22) have shown that the implantation of BM-
NCs, BM-MSCs, and AD-MSCs into the damaged
eart can improve cardiac function, likely through paracrine
echanisms, with rare events of myogenic differentiation.
espite the paucity of direct regeneration of new myocar-
ium from these stem cells of extracardiac origin, the
mprovement of cardiac function reported in previous ran-
omized clinical trials is encouraging (10–18).
One distinctive feature of resident cardiac stem cells is their
bility to undergo consistent cardiomyogenic and angiogenic
ifferentiation (1–9,23–25), a finding confirmed here. Al-
hough almost 10% of CDCs expressed troponin T in vitro,
uman CDCs expressing -SA were infrequently observed in
he infarcted hearts of SCID mice 3 weeks after treatment.
urthermore, we did not examine whether these -SA–
positive human CDCs were physiologically integrated
with the resident cardiomyocytes of mice. Therefore,
regeneration of new functional myocardium directly from
the implanted human CDCs is a consistent finding but
one of questionable significance. The present evidence
supports the notion that mechanism of functional benefit
after CDC implantation, as with other cell types, is
predominantly dependent on paracrine effects and re-
cruitment of endogenous regeneration (25).
We thus compared the secretion of growth factors that
TUNEL)-positive cells in the infarcted hearts of mice 3 weeks after cell treatment
L-positive cells in the myocardium of mice treated with different cell types and
and 4.eling (
TUNE
res 1generally are recognized to play critical roles in angiogene-
950 Li et al. JACC Vol. 59, No. 10, 2012
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growth factor was undetectable in media conditioned by any
of the 4 cell types, but, beyond even our own expectations,
CDCs robustly produced a variety of growth factors, in-
cluding angiopoietin, bFGF, HGF, IGF-1, SDF-1, and
VEGF. Although BM-MSCs, AD-MSCs, and BM-
MNCs could produce some of these factors in levels
comparable to CDCs, the paracrine profile was uniquely
well balanced in CDCs. The robust production of diverse
paracrine factors by CDCs provides a potential mechanism
underlying their superiority for functional myocardial repair,
but further research will be required to understand the
precise role of each paracrine factor, as well as the roles of
others known to be secreted but not quantified here (37).
The use of the same medium (IMDM) for all cell types
avoids possible confounding effects due to different culture
conditions; nevertheless, the fact that cells were cultured
uniformly may minimize favorable features unique to each
cell type that might be more apparent with media optimized
for each cell type.
Tube formation assays are commonly used to measure the
angiogenic potential of endothelial cells (36). The superi-
Figure 7 Ventricular Remodeling
(A) Representative images of Masson’s staining of infarcted mice hearts after imp
ses (n  3 mice per group) of (B) left ventricular wall thickness and (C) infarct pe
compared with BM-MSCs, AD-MSCs, and BM-MNC treatment, although implantatio
control treatment with saline injection only. Abbreviations as in Figure 1.ority of tube formation observed in CDCs indicates theirangiogenic potential, which is in agreement with CDCs’
robust secretion of pro-angiogenic cytokines (Fig. 2). The
observation that BM-MNCs failed to form any tubes may
be due to the fact that MNCs need a longer time (24 h) to
form tubes (36), whereas we performed the assay at the 6-h
time point. Because we did not stain for endothelial markers
(e.g., CD31), it is unknown whether these tube structures
actually represent endothelial cells differentiated from the
various cell types. Indeed, it has been reported that mesen-
chymal and fibroblast cells assist in blood vessel formation
by aligning into tube networks (38).
We also found CDCs were more resistant to oxidative
stress-induced apoptosis in vitro (Online Figs. 4 and 5) and
MI-induced apoptosis in vivo (Fig. 5). The superiority of
CDCs to other cell types in enhancing host tissue preser-
vation is striking. Therefore, it is conceivable that this action
is responsible for the superior impact of CDCs in terms of
preserving cardiac function and attenuating pathological
remodeling, although the relative importance of the various
favorable effects remains to be defined. It should be noted
that we assayed apoptosis in vivo 3 weeks after myocardial
infarction/cell treatment. At that time point, the acute
ion of different types of human cells or saline injection only. Quantitative analy-
r show that remodeling was attenuated more efficiently by CDC implantation,
M-MSCs, AD-MSCs, and BM-MNCs resulted in less remodeling compared withlantat
rimete
n of Bphase of cell death due to ischemia might have already
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tion of long-term remodeling and heart failure. One limi-
tation of this experiment is that we did not perform double
staining for TUNEL- and HNA-positive nuclei. Therefore,
we cannot distinguish whether apoptosis is reduced in
endogenous cells, transplanted cells, or both. In addition,
our results do not exclude the possibility that different levels
of inflammatory infiltration among groups might contribute
to observed differences in apoptotic rates. Nevertheless, the
superior tissue preservation capacity of CDCs is consistent
with their robust secretion of antiapoptotic and pro-
angiogenic factors.
We did not include a number of other stem cell types in
our comparison, including myoblasts and peripheral blood–
derived endothelial progenitors, although they have already
been tested in clinical trials (17,18). The major reason is the
relative lack of enthusiasm in the field for these cell types as
candidates for further clinical development for cardiac
regeneration (although endothelial progenitors do have
positive effects on angina and critical limb ischemia [17]).
We also did not select embryonic stem cell- or induced
pluripotent stem cell-derived cardiomyocytes for compari-
son because they are far from clinical applicability at present,
although both may excel in the direct production of new
functional myocardium (39,40).
We did, however, compare the therapeutic potency of
cardiac progenitor cells purified by virtue of their c-kit-
positivity (35,41), relative to unselected CDCs (42). We
confirmed the reported ability of c-kit cardiac cells to
oost cardiac function post-infarction (1,9), but we discov-
red that c-kit cells are not as potent as the CDC mixture
ither in terms of functional benefit or in paracrine factor
ecretion. One trivial explanation for this finding would be
Figure 8 Comparison of Purified c-kit Stem Cells and Unsorte
(A) 3 weeks after infarction, left ventricular ejection fraction (LVEF) was higher in m
CDCs, although these purified c-kit stem cells also improved cardiac function wh
cells was used for culture, the purified c-kit stem cells released fewer VEGF, SDFntibody-related interference with cell potency, but weelieve that is unlikely. The c-kit antibody used (43) has
een shown to interfere minimally with ligand binding,
eceptor phosphorylation, and internalization in c-kit–
xpressing cell lines (44). Also, magnetic-activated cell
orting for mast cells using this c-kit antibody neither
nduced histamine release nor impaired the ability of cells to
elease histamine when stimulated (45). We must acknowl-
dge, however, that subtle differences in specific sorting and
ulture methods for c-kit cells may affect the efficacy of the
cells. Nevertheless, the finding that the natural CDC
mixture is superior to the purified c-kit subpopulation adds
a new dimension to the emerging notion that mesenchymal
cells favor endogenous cardiac regeneration (10,46), at least
partly via the attraction of c-kit cells. We conjecture that
the stromal and mesenchymal cells synergize with the c-kit
cells in the natural CDC mixture to enhance overall
paracrine potency and thereby boost functional benefit;
alternatively, c-kit cells may be tangential to the mecha-
ism of benefit of CDCs. More experiments are required to
esh out these ideas.
onclusions
n this first comprehensive head-to-head comparison of 4
ifferent cell types in the same animal model in the same
aboratory, with blinded analysis, CDCs were superior in
erms of paracrine factor secretion, angiogenesis, car-
iomyogenic differentiation, ischemic tissue preservation,
ntiremodeling effects, and functional benefit. The CDC
ixture was more potent than the c-kit subpopulation.
Ongoing and future clinical studies will serve as the ultimate
test of potency, but the present results give good reason for
Cs
at received unsorted CDCs than those with c-kit cells purified from the same
pared with controls injected with saline only. (B) Although the same number of
, and HGF than the unsorted CDCs. Abbreviations as in Figures 1 and 2.d CD
ice th
en com
, IGF-1optimism regarding the therapeutic potential of CDCs.
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using cardiosphere-derived cells: Makkar RR, Smith RR,
Cheng K, et al. Intracoronary cardiosphere-derived cells for
heart regeneration after myocardial infarction (CADU-
CEUS): a prospective, randomised phase 1 trial. Lancet
2012 Feb 14 [E-pub ahead of print]; doi:10.1016/S0140-
6736(12)60195-0.
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APPENDIX
For supplemental figures on the study results,
please see the online version of this article.
